Related Experiment Video

Updated: Aug 16, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

NS-398, a selective cyclooxygenase-2 inhibitor, reduces experimental bladder carcinoma outgrowth by inhibiting tumor

Niels Smakman1, Nicoline Schaap, Cristel M J T Snijckers

  • 1Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.

Urology
|August 16, 2005
PubMed
Abstract

Insights

Selective COX-2 inhibition with NS-398 effectively reduced T24 bladder carcinoma growth in mice. This therapeutic effect was primarily due to decreased tumor cell proliferation, not altered survival or vascularization.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Cyclooxygenase-2 (COX-2) is overexpressed in bladder carcinoma, correlating with advanced stage and poor patient survival.
  • Selective COX-2 inhibition presents a potential therapeutic strategy for bladder cancer.

Purpose of the Study:

  • To evaluate the efficacy of the selective COX-2 inhibitor NS-398 against experimental T24 bladder carcinoma.
  • To assess NS-398's impact on tumor cell proliferation, survival, and vascularization.

Main Methods:

  • T24 bladder carcinoma cells were treated with NS-398 in vitro and in an orthotopic mouse model.
  • Noninvasive monitoring of tumor growth was achieved using firefly luciferase lentiviral transduction.
  • Immunohistochemistry assessed proliferation (Ki-67), apoptosis (cleaved caspase-3), and angiogenesis (CD31, von Willebrand factor).

Main Results:

  • NS-398 inhibited prostaglandin E2 (PGE2) secretion and dose-dependently reduced T24 cell proliferation in vitro without affecting viability.
  • In vivo, NS-398 significantly reduced orthotopic T24 bladder carcinoma outgrowth.
  • This reduction was associated with decreased Ki-67-positive cells, but not with changes in tumor cell viability or vascularization.

Conclusions:

  • Selective COX-2 inhibition using NS-398 demonstrates therapeutic efficacy in an orthotopic mouse model of T24 human bladder carcinoma.
  • The primary mechanism of action appears to be the inhibition of tumor cell proliferation, rather than effects on angiogenesis or cell survival.

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...